Johnson & Johnson (JNJ) Investor Update summary

Litigation update and strategic response

• Recent bankruptcy court ruling dismissed the proposed settlement plan, despite 85% claimant support, due to disputed voting practices by a key law firm.

• The company will reverse $7 billion of previously held reserves, reflecting its intent not to settle or pay on claims it deems meritless.

• Focus shifts back to the tort system, with confidence in prevailing based on a strong historical win record in ovarian cancer cases.

• Immediate next steps include pursuing Daubert challenges to exclude plaintiff experts and seeking disqualification of the opposing law firm.

• Expectation of court rulings on key motions within six months, which could significantly reduce the number of viable claims.

Financial and operational outlook

• Reversal of $7 billion in reserves strengthens financial position, with no impact on 2025 guidance or long-term projections.

• Free cash flow remains robust, with $20 billion generated last year and continued investment in R&D and strategic acquisitions.

• Recent product pipeline advancements in both Innovative Medicine and MedTech support confidence in future growth.

Broader litigation environment and policy stance

• Mass tort litigation is increasingly driven by third-party financing, including foreign sovereign wealth funds, raising public policy concerns.

• The company is advocating for civil justice reform and greater scrutiny of litigation financing and junk science in court proceedings.

• Leadership role is emphasized in challenging meritless claims and promoting judicial reforms to protect business innovation and capital allocation.